John Reed, Sanofi R&D chief (Jeff Rumans)

Am­i­cus shares surge as Sanofi strug­gles to raise a cheer for mixed piv­otal da­ta for a PhI­II con­tender — and an­a­lysts blow a rasp­ber­ry

Sanofi took ex­tra time on Tues­day to of­fer an up­beat as­sess­ment of its top-line re­sults for a piv­otal study of a new ERT for late-on­set Pompe dis­ease. But with Am­i­cus breath­ing down its neck with a Phase III ri­val of its own, the phar­ma gi­ant was treat­ed to some un­wel­come re­views from a slate of an­a­lysts cov­er­ing the matchup.

“Meh,” summed up Cowen’s Ritu Bar­al in the head­line, which helps ex­plain why Am­i­cus’ stock shot up 17%.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.